Who
Cathy Klema
Director
Company insider
Files Form 4 as: Director, OptimizeRx; Director, Allergan; Director, Actavis; Director, Pharmaceutical Product Development.
In numbers
- Trades disclosed
- 89
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $3.0M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 3 Jan 2006
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —34,517 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —34,517 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —9,868 at $0.00 | filing |
| 2 Feb 2025filed 4 Feb 2025 | OPRX OptimizeRxoption or derivative · Business Services | SEC FORM 4 Code M | —5,109 at $0.00 | filing |
| 2 Feb 2025filed 4 Feb 2025 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code M | —5,109 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | OPRX OptimizeRxBusiness Services | SEC FORM 4 Code A | —6,643 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | OPRX OptimizeRxoption or derivative · Business Services | SEC FORM 4 Code A | —5,109 at $0.00 | filing |
| 30 Apr 2019filed 2 May 2019 | Allergan | SEC FORM 4 Code F | $140K953 at $147.00 | filing |
| 11 Mar 2019filed 13 Mar 2019 | Allergan | SEC FORM 4 Code J | —410 at $0.00 | filing |
| 2 May 2018filed 4 May 2018 | Allergan | SEC FORM 4 Code A | $300K1,985 at $151.07 | filing |
| 4 May 2017filed 5 May 2017 | Allergan | SEC FORM 4 Code A | $300K1,223 at $245.25 | filing |
| 8 Aug 2016filed 9 Aug 2016 | Allergan | SEC FORM 4 Code A | $50K201 at $248.31 | filing |
| 5 May 2016filed 9 May 2016 | Allergan | SEC FORM 4 Code A | $250K1,188 at $210.34 | filing |
| 5 Jun 2015filed 30 Jun 2015 | Allergan | SEC FORM 4 Code A | $250K826 at $302.30 | filing |
| 5 Jun 2015filed 8 Jun 2015 | Actavis | SEC FORM 4 Code A | $250K826 at $302.30 | filing |
| 4 Jun 2015filed 30 Jun 2015 | Allergan | SEC FORM 4 Code F | $167K549 at $303.38 | filing |
| 4 Jun 2015filed 8 Jun 2015 | Actavis | SEC FORM 4 Code F | $167K549 at $303.38 | filing |
| 9 May 2014filed 13 May 2014 | Actavis | SEC FORM 4 Code A | $225K1,142 at $197.05 | filing |
| 1 Oct 2013filed 3 Oct 2013 | Actavis | SEC FORM 4 Code A | —19,608 | filing |
| 1 Oct 2013filed 2 Oct 2013 | Actavis | SEC FORM 4 Code D | —19,608 | filing |
News
No headline names them, or the companies they trade most, lately.